GH31 / Genhouse Bio, Gilead - LARVOL DELTA

Gilead's latest synthetic lethal therapy comes via $1.5B deal with China's Genhouse (FierceBiotech) - "The Suzhou-based biotech has been developing the MAT2A-targetting synthetic lethal therapy, dubbed GH31, for various tumor types...As well as the upfront payment, Genhouse will be in line for up to $1.45 billion in milestone payments as well as royalties based on tiered double-digit percentages on net sales."

Licensing / partnership • Solid Tumor